|
| 瑞舒伐他汀对2型糖尿病患者的血脂及血管内皮功能的影响 |
| Effect of Rosuvastatin on Serum Levels of Willebrand Factor and Thrombomodulin of Patients with Type 2 Diabetes Mellitus |
| |
| DOI： |
| 中文关键词: 2型糖尿病 瑞舒伐他汀 血清血管性血友病因子 凝血酶调节蛋白 血脂 |
| 英文关键词:Type 2 diabetes mellitus Rosuvastatin von Willebrand factor Thrombomodulin Blood fat |
| 基金项目: |
|
| 摘要点击次数: 1177 |
| 全文下载次数: 939 |
| 中文摘要: |
| 摘 要 目的:探讨瑞舒伐他汀对2型糖尿病患者的血脂及血清血管性血友病因子（vWF）、凝血酶调节蛋白（TM）水平的影响。方法：80例2型糖尿病患者随机分为观察组和对照组。两组患者均在饮食调整、适当体育锻炼基础上予以口服降糖药或胰岛素注射治疗。观察组患者加用瑞舒伐他汀片10 mg，po qd，连用12周。比较两组患者治疗前后血脂、血清vWF和TM水平变化及药品不良反应。结果：治疗12周后，观察组总胆固醇（TC）、三酰甘油（TG）和低密度脂蛋白胆固醇（LDL-C）水平均有不同程度下降，高密度脂蛋白胆固醇（HDL-C）水平明显上升(P<0.05)；而对照组治疗前后TC、TG、LDL-C和HDL-C水平变化不明显(P>0.05)；两组患者血清vWF和TM水平均有不同程度下降(P<0.05或0.01)，且观察组下降幅度较对照组更明显(P<0.05)。两组患者治疗中未见明显药品不良反应。结论：瑞舒伐他汀能调节2型糖尿病患者的血脂代谢紊乱，安全性较佳，并能降低患者血清vWF和TM水平，保护和修复血管内皮细胞损伤或调节内皮功能紊乱，在减少与预防心脑血管并发症中起到重要作用。 |
| 英文摘要: |
| ABSTRACT Objective:To discuss the effect of rosuvastatin on serum levels of von Willebrand factor(vWF) and thrombomodulin(TM) of patients with type 2 diabetes mellitus. Methods:80 cases of patients with type 2 diabetes mellitus were randomly divided into observation group and control group. The patients in the two groups were given antidiabetic drugs through the mouth or insulin by injection on the basis of diet adjustment and proper exercises with guidance and in accordance with condition needs and eating habits. The patients in the observation group were additionally given 10mg rosuvastatin tablets once a day for 12 weeks. The changes of the blood fat, drug adverse reaction and serum vWF and TM levels of the patients in the two groups were compared before and 12 weeks after the treatment. Results:12 weeks after the treatment, TC, TG and LDL-C levels in the observation group all declined at different degrees (P<0.05), while the HDL-C level obviously rose (P<0.05), and the changes of TC, TG, LDL-C and HDL-C levels in the control group were not obvious (P>0.05). Meanwhile, the serum vWF and TM levels of the patients in the two groups all declined to different extents (P<0.05 or 0.01), and the declining rate in the observation group was much more obvious than that in the control group (P<0.05). There was no obvious drug adverse reaction in the two groups during the treatment. Conclusion: Rosuvastatin could adjust the lipid metabolism disorder of patients with type 2 diabetes mellitus with favorable lipid lowering effect and security, which could reduce serum vWF and TM levels of patients with type 2 diabetes mellitus, protect and rehabilitate endothelial injury or adjust endothelial dysfunction and play an important role in reducing and preventing the cardiovascular complications. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
